# OnCo record parp (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/parp/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "parp" ;
  schema:name "PARP"@en ;
  schema:alternateName "PARP1"@en, "PARP1/2 inhibitor class"@en, "PARP1" ;
  schema:description "PARP inhibitors block DNA repair. Some cancers with defective repair are especially vulnerable, but the gene, disease setting and treatment combination determine which evidence applies."@en ;
  schema:url <https://onco.cc/targets/parp/> ;
  schema:dateModified "2026-10-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/PARP_inhibitor>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:270>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143799>, <https://www.uniprot.org/uniprotkb/P09874/entry>, <https://www.ncbi.nlm.nih.gov/gene/142> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7118227> ;
  schema:citation <https://en.wikipedia.org/wiki/PARP_inhibitor>, <https://doi.org/10.1200/JCO-25-02075>, <https://doi.org/10.1200/JCO.20.02151>, <https://clinicaltrials.gov/study/NCT06167317>, <https://clinicaltrials.gov/study/NCT05417594> ;
  onco:tag "synthetic-lethality" ;
  onco:targetClass "enzyme" ;
  onco:firstDescribed "1987"^^xsd:gYear ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:drugs <https://onco.cc/drugs/saruparib/>, <https://onco.cc/drugs/palacaparib/>, <https://onco.cc/drugs/eik1004/>, <https://onco.cc/drugs/hrs-1167/>, <https://onco.cc/drugs/nms-03305293/>, <https://onco.cc/drugs/gs-0201/>, <https://onco.cc/drugs/hs-10502/>, <https://onco.cc/drugs/snv1521/>, <https://onco.cc/drugs/dsb2455/>, <https://onco.cc/drugs/imp1734/>, <https://onco.cc/drugs/vb15010/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/rucaparib/> ;
  onco:pathways <https://onco.cc/pathways/ddr/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/>, <https://onco.cc/key-papers/paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017/> .